Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
    • 指導教授
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 醫學院
  3. 生物化學暨分子生物學科研究所
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40685
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor周綠蘋
dc.contributor.authorYen-Ching Changen
dc.contributor.author張晏菁zh_TW
dc.date.accessioned2021-06-14T16:55:55Z-
dc.date.available2013-08-08
dc.date.copyright2008-08-08
dc.date.issued2008
dc.date.submitted2008-07-29
dc.identifier.citationReferences:
1. Yamamoto, S., Tomita, Y., Hoshida, Y., Iizuka, N., Monden, M., Iuchi, K., and Aozasa, K. (2004) Ann Surg Oncol 11, 697-704
2. Tsujimoto, Y., Tomita, Y., Hoshida, Y., Kono, T., Oka, T., Yamamoto, S., Nonomura, N., Okuyama, A., and Aozasa, K. (2004) Clin Cancer Res 10, 3007-3012
3. Yamamoto, S., Tomita, Y., Hoshida, Y., Iizuka, N., Kidogami, S., Miyata, H., Takiguchi, S., Fujiwara, Y., Yasuda, T., Yano, M., Nakamori, S., Sakon, M., Monden, M., and Aozasa, K. (2004) Clin Cancer Res 10, 5558-5565
4. Yamamoto, S., Tomita, Y., Hoshida, Y., Nagano, H., Dono, K., Umeshita, K., Sakon, M., Ishikawa, O., Ohigashi, H., Nakamori, S., Monden, M., and Aozasa, K. (2004) Ann Surg Oncol 11, 165-172
5. Yamamoto, S., Tomita, Y., Hoshida, Y., Sakon, M., Kameyama, M., Imaoka, S., Sekimoto, M., Nakamori, S., Monden, M., and Aozasa, K. (2004) Clin Cancer Res 10, 651-657
6. Yamamoto, S., Tomita, Y., Hoshida, Y., Takiguchi, S., Fujiwara, Y., Yasuda, T., Yano, M., Nakamori, S., Sakon, M., Monden, M., and Aozasa, K. (2003) J Clin Oncol 21, 2537-2544
7. Yamamoto, S., Tomita, Y., Hoshida, Y., Toyosawa, S., Inohara, H., Kishino, M., Kogo, M., Nakazawa, M., Murakami, S., Iizuka, N., Kidogami, S., Monden, M., Kubo, T., Ijuhin, N., and Aozasa, K. (2004) Ann Oncol 15, 1432-1438
8. Yamamoto, S., Tomita, Y., Nakamori, S., Hoshida, Y., Nagano, H., Dono, K., Umeshita, K., Sakon, M., Monden, M., and Aozasa, K. (2003) J Clin Oncol 21, 447-452
9. Yamamoto, S., Tomita, Y., Uruno, T., Hoshida, Y., Qiu, Y., Iizuka, N., Nakamichi, I., Miyauchi, A., and Aozasa, K. (2005) Ann Surg Oncol 12, 925-934
10. Zucchini C, R. A., Manara MC, De Sanctis P, Capanni C, Bianchini M, Carinci P, Scotlandi K, Valvassori L. ( 2008 Jan) Int J Oncol. 32, 17-31
11. Asai, T., Tomita, Y., Nakatsuka, S., Hoshida, Y., Myoui, A., Yoshikawa, H., and Aozasa, K. (2002) Jpn J Cancer Res 93, 296-304
12. Vandermoere, F., El Yazidi-Belkoura, I., Slomianny, C., Demont, Y., Bidaux, G., Adriaenssens, E., Lemoine, J., and Hondermarck, H. (2006) J Biol Chem 281, 14307-14313
13. Chan CH, K. C., Chang JG, Chen SF, Wu MS, Lin JT, Chow LP. (2006 Apr) Mol Cell Proteomics 5(4), 702-713
14. Marshall, B. J. a. W., J.R. (1984) Lancet, , 1311-1315.
15. (1994) Lyon, 15-22
16. Konturek, P. C., Konturek, S.J., Pierzchalski, P., Bielanski, W., Duda, A., Marlicz, K., Starzynska, T. and Hahn, E.G. (2001) Med Sci Monit 7, 1092-1107.
17. Frohlich, K. U., Fries, H. W., Rudiger, M., Erdmann, R., Botstein, D., and Mecke, D. (1991) J Cell Biol 114, 443-453
18. Pamnani, V., Tamura, T., Lupas, A., Peters, J., Cejka, Z., Ashraf, W. and Baumeister, W. ((1997)) FEBS Lett, 263-268
19. Peters, J. M., Walsh, M.J. and Franke, W.W. (1990) Embo J, 9, 1757-1767.
20. Neuwald, A. F., Aravind, L., Spouge, J.L. and Koonin, E.V ((1999)) Genome Res, 9, 27-43.
21. Braun, R. J., and Zischka, H. (2008) Biochim Biophys Acta 1783, 1418-1435
22. Woodman, P. G. (2003) J Cell Sci, 116, 4283-4290
23. Hershko, A. a. C., A. (1998) Annu Rev Biochem 67,, 425-479
24. Dai, R. M. a. L., C.C. (2001) Nat Cell Biol 3, 740-744.
25. Dai, R. M., Chen, E., Longo, D.L., Gorbea, C.M. and Li, C.C. (1998) J Biol Chem 273, 3562-3573
26. Koegl, M., Hoppe, T., Schlenker, S., Ulrich, H.D., Mayer, T.U. and Jentsch, S. A , , . (1999) Cell 96, 635-644
27. Meyer, H. H., Shorter, J.G., Seemann, J., Pappin, D. and Warren, G. (2000) Embo J, 19, 2181-2192.
28. Kaneko, C., Hatakeyama, S., Matsumoto, M., Yada, M., Nakayama, K. and Nakayama, K.I. (2003) Biochem Biophys Res Commun 300, 297-304
29. Kondo, H., Rabouille, C., Newman, R., Levine, T.P., Pappin, D., Freemont, P. and Warren, G. (1997) Nature 388, 75-78
30. Rothman, J. E. a. W., G. (1994) Curr Biol 4, 220-233.
31. Rabouille, C., Kondo, H., Newman, R., Hui, N., Freemont, P. and Warren, G. . (1998) Cell 92, 603-610.
32. Rabouille, C., Kondo, H., Newman, R., Hui, N., Freemont, P. and Warren, G. (1998) Cell 92, 603-610
33. Kozutsumi, Y., Segal, M., Normington, K., Gething, M.J. and Sambrook, J. (1988) Nature 332, 462-464
34. Ye, Y., Meyer, H.H. and Rapoport, T.A. ((2001)) Nature 414, 652-656
35. Rabinovich, E., Kerem, A., Frohlich, K.U., Diamant, N. and Bar-Nun, S. ,. (2002)Mol Cell Biol 22, 626-634
36. Meusser, B., Hirsch, C., Jarosch, E. and Sommer, T. (2005) Nat Cell Biol 7, 766-772
37. Ghosh, S., May, M.J. and Kopp, E.B. (1998) Annu Rev Immunol, 225-260
38. Karin, M. a. B.-N., Y. (2000) Annu Rev Immunol, 621-663
39. Lin, L. a. G., S. (1996) AMol Cell Biol, 2248-2254
40. Moir, D., Stewart, S.E., Osmond, B.C. and Botstein, D. (1982) Genetics, 547-563.
41. Egerton, M., Ashe, O.R., Chen, D., Druker, B.J., Burgess, W.H. and Samelson, L.E., (1992) Embo J, , 3533-3540
42. Yamada, T., Okuhara, K., Iwamatsu, A., Seo, H., Ohta, K., Shibata, T. and Murofushi, H. (2000) FEBS Lett, , 287-291.
43. Zhang, H., Wang, Q., Kajino, K. and Greene, M.I. (2000)DNA Cell Biol, , 253-263
44. Nakayama, K. I. a. N., K. . ((2006) ) Nat Rev Cancer 369-381
45. 110. Yang, Y. a. Y., X. . ((2003)) Faseb J, , 790-799
46. Shirogane, T., Fukada, T., Muller, J.M., Shima, D.T., Hibi, M. and Hirano, T. ((1999)) Immunity, 709-719.
47. Imamura, S., Ojima, N. and Yamashita, M. (2003)FEBS Lett, 14-20.
48. Wu, D., Chen, P.J., Chen, S., Hu, Y., Nunez, G. and Ellis, R.E. (1999) Development, 2021-2031
49. Wang, Q., Song, C. and Li, C.C. (2004) J Struct Biol, 44-57
50. Yeung, H. O., Kloppsteck, P., Niwa, H., Isaacson, R. L., Matthews, S., Zhang, X., and Freemont, P. S. (2008) Biochem Soc Trans 36, 62-67
51. Meyer, H. H., Wang, Y., and Warren, G. (2002) EMBO J 21, 5645-5652
52. Allen, M. D., Buchberger, A., and Bycroft, M. (2006) J Biol Chem 281, 25502-25508
53. A.D., M. (1992) nature, 455 - 460
54. He TC, Z. S., da Costa LT, Yu J, Kinzler KW, Vogelstein B. (1998 Mar ) Proc Natl Acad Sci. , 2509-2514
55. McClellan, A. J., Xia, Y., Deutschbauer, A. M., Davis, R. W., Gerstein, M., and Frydman, J. (2007) Cell 131, 121-135
56. Mayer, M. P., and Bukau, B. (1998) Biol Chem 379, 261-268
57. Prince, T., Shao, J., Matts, R. L., and Hartson, S. D. (2005) Biochem Biophys Res Commun 331, 1331-1337
58. Grelle, G., Kostka, S., Otto, A., Kersten, B., Genser, K. F., Muller, E. C., Walter, S., Boddrich, A., Stelzl, U., Hanig, C., Volkmer-Engert, R., Landgraf, C., Alberti, S., Hohfeld, J., Strodicke, M., and Wanker, E. E. (2006) Mol Cell Proteomics 5, 234-244
59. Mayer, M. P., and Bukau, B. (2005) Cell Mol Life Sci 62, 670-684
60. Yokota, S., Yamamoto, Y., Shimizu, K., Momoi, H., Kamikawa, T., Yamaoka, Y., Yanagi, H., Yura, T., and Kubota, H. (2001) Cell Stress Chaperones 6, 345-350
61. Munoz, M. E., and Ponce, E. (2003) Comp Biochem Physiol B Biochem Mol Biol 135, 197-218
62. Schulze, G. (2000) Anticancer Res 20, 4961-4964
63. Gray, D., Jubb, A. M., Hogue, D., Dowd, P., Kljavin, N., Yi, S., Bai, W., Frantz, G., Zhang, Z., Koeppen, H., de Sauvage, F. J., and Davis, D. P. (2005) Cancer Res 65, 9751-9761
64. Ghislain, M., Dohmen, R. J., Levy, F., and Varshavsky, A. (1996) EMBO J 15, 4884-4899
65. Buchberger, A., Howard, M. J., Proctor, M., and Bycroft, M. (2001) J Mol Biol 307, 17-24
66. Hong, Y. R., Chen, C. H., Chuo, M. H., Liou, S. Y., and Howng, S. L. (2000) Biochem Biophys Res Commun 279, 989-995
67. Hong, Y. R., Chen, C. H., Chang, J. H., Wang, S., Sy, W. D., Chou, C. K., and Howng, S. L. (2000) Biochim Biophys Acta 1492, 513-516
68. Ma, K., Cheung, S. M., Marshall, A. J., and Duronio, V. (2008) Cell Signal 20, 684-694
69. Vanden Berghe, T., Kalai, M., van Loo, G., Declercq, W., and Vandenabeele, P. (2003) J Biol Chem 278, 5622-5629
70. Ward, J., Cox, M., Trussell, B., Benghuzzi, H., Tucci, M., Tsao, A., and Hughes, J. (2002) Biomed Sci Instrum 38, 197-202
71. McFate, T., Mohyeldin, A., Lu, H., Thakar, J., Henriques, J., Halim, N. D., Wu, H., Schell, M. J., Tsang, T. M., Teahan, O., Zhou, S., Califano, J. A., Jeoung, N. H., Harris, R. A., and Verma, A. (2008) J Biol Chem
72. Katoh, M. (2007) Cancer Biol Ther 6, 832-839
73. Vandermoere, F., El Yazidi-Belkoura, I., Demont, Y., Slomianny, C., Antol, J., Lemoine, J., and Hondermarck, H. (2007) Mol Cell Proteomics 6, 114-124
74. Klein, J. B., Barati, M. T., Wu, R., Gozal, D., Sachleben, L. R., Jr., Kausar, H., Trent, J. O., Gozal, E., and Rane, M. J. (2005) J Biol Chem 280, 31870-31881
75. Falsone, S. F., Gesslbauer, B., Tirk, F., Piccinini, A. M., and Kungl, A. J. (2005) FEBS Lett 579, 6350-6354
76. Markham, K., Bai, Y., and Schmitt-Ulms, G. (2007) Anal Bioanal Chem 389, 461-473
77. Phizicky, E. M., and Fields, S. (1995) Microbiol Rev 59, 94-123
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40685-
dc.description.abstract過去本實驗室利用蛋白質體學技術(proteomics approach)以及免疫組織染色,對照未感染幽門螺旋桿菌以及感染幽門螺旋桿菌的AGS 胃腺癌細胞,發現許多經幽門螺旋桿菌感染後表現量會上升的蛋白質,有些蛋白質為已知可能之治癌因子,其中又以缬絡胺酸蛋白質valosin containing protein (VCP)這個重要蛋白質表現差異最大,稍後利用mRNA微陣列結合蛋白質體學,得到許多可能受VCP調控之宿主細胞因子。至今缬絡胺酸的研究領域當中,發現許多種類癌症都有大量表現的情形,並在病人組織中的缬絡胺酸含量可以做為癌症預後狀況的指標。然而缬絡胺酸與癌症發展之間的關係尚未完全研究清楚,本論文的實驗目的希望利用蛋白質體學技術,研究AGS 胃腺癌細胞大量表現,利用免疫沉澱(immunoprecipitation)方法,觀察細胞質中與缬絡胺酸交互作用的蛋白質並進一步探討之。
嘗試過不同的轉染方式後,我們採用帶有表現綠色螢光蛋白且尾端接上flag tag缬絡胺酸質體感染胃上皮細胞,使之大量表現缬絡胺酸,也由於在細胞質中表現,因此利用接有辨認flag tag抗體的凝膠珠去把跟缬絡胺酸於胃上皮細胞正常生理下有交互作用蛋白質一併抓下,此過程稱之為共免疫沉(co-immunoprecipitation),抓下來的蛋白質複合體,則採取蛋白質體學的方式,經過一維電泳展開複合體組成蛋白質合併液相層析偶合串聯式質譜儀來分析與單有表現綠色螢光蛋白的胃上皮細胞也進行免疫沉澱的相比較,扣除掉非專一性結合的蛋白質後,我們找到有158個有差異的蛋白質,依蛋白質功能粗略的分為:1.蛋白質合成與蛋白質摺疊之相關因子; 2. 細胞骨架蛋白質; 3.細胞代謝酵素; 4.轉錄與轉譯相關因子;5其他。參考文獻之後,我們選出其中的30個與癌症相關蛋白質,並利用訊息傳遞資料庫的分析將鑑定的結果進一步推測出可能之訊息傳遞網路,其中較有可能藉由缬絡胺酸的分子導護幫助進行傳導的訊息途徑有二,一為腫瘤抑制因子p53與DNA修復的訊息傳導,二為因缺氧環境而產生的代謝途徑的適應。然而這些訊息傳導途徑皆導向更上游經PKB/Akt訊息傳導所共同調控,未來可望將這些結果做更進一步的討論,以利於在VCP於胃上皮細胞中參與調控的致病機制進一步的發現。
zh_TW
dc.description.abstractBy using proteomics approaches and immunohistocehmistry in the past, our laboratory found that the protein expression level of many cancer-related factors were elevated in AGS cells after H. pylori infection, and one important factor was valosin-containing protein (VCP). Recently studies are showed that VCP overexpresses in almost every kind of cancer, and the level of VCP in cancerous tissues is a prognosis marker for cancer diseases. However it is not a clear relationship between VCP expression level and cancer development. The specific aim of this thesis is to investigate the interacting proteins with VCP. By overexpressing VCP in AGS cells and co-immunoprecipitating the whole complexes, further the complexes are identified by using proteomics approaches.
The number of identification proteins deducting from nonspecific binding proteins is 158. These were classified as transcription and translation-related proteins and folding-related proteins, cytoskeleton proteins, metabolic enzymes, cell communication/ signal transduction-related proteins on the basis of their molecular functions. After literature search, we select 30 proteins which are more significant in cancer development and H. pylori infection. The Metacore help in linking these proteins and producing possible signal network. There are two depended on the analysis: (1) ATM-Chk2-p53 cascade and (2) VHL-HIF1 pathway. VCP as a molecular chaperone may promote degradation of p53 and VHL-HIF and therefore cells are anti-apoptosis. And the two pathways are both PKB/Akt downstream signal pathway. VCP was also documented to play an essential role in Akt downstream signaling, so we proposed the aforementioned findings were caused by the facilitation of Akt signaling in VCP-overexpressed cells. Therefore, we hope the complete interactome can be identified so that we can study the detail mechanism of VCP in cancer development.
en
dc.description.provenanceMade available in DSpace on 2021-06-14T16:55:55Z (GMT). No. of bitstreams: 1
ntu-97-R95442023-1.pdf: 2131116 bytes, checksum: 51a2a3b7dc41fa5d1062f6d4a79e1a34 (MD5)
Previous issue date: 2008
en
dc.description.tableofcontents致謝. i
Abstract in Chinese...... ii
Abstract.. iii
Table of Contents... iv
Abbreviations .... 1
Chapter 1 Introduction. 3
1.1 VCP as a gastric cancer crucial biomarker .... 4
1.2 The sctructure of VCP.. 6
1.3 The functions of VCP... 7
1.3.1 Ubiquitin/proteasome-mediated protein degradation ... 7
1.3.2 Membrane fusion.. 8
1.3.3 ER-associated degradation ..... 9
1.3.4 Transcription factors activation . 10
1.3.5 Cell cycle regulation....11
1.3.6 Inhibition of apoptosis..... 12
1.3.7 Molecular chaperone .. 13
1.4 Domains for diverse cofactors and adapters..... 14
1.5 The aims of this paper ... 15
Chapter 2 Materials ... 16
2.1 Gastric cancer cell line: . 16
2.2 Instruments and equipments:... 16
2.3 Enzyme ... 17
2.4 Kit and medicine.... 17
2.5 Software and database ... 18
Chapter 3 Methods .... 19
3.1 Preparation of medium .. 19
3.2 Cell culture .. 19
3.3 Transfection . 19
3.3.1 Clacium phosphate method .. 20
3.3.2 Adenovirus infection .. 21
3.4 Preparation of total proteins from AGS cells.... 21
3.5 BCA protein assay Reagent (Pierce) . 21
3.6 Immunoprecipitaiton .. 22
3.7 TCA precipitation .. 23
3.8 SDS-PAGE of total proteins from AGS cells ... 23
3.9 Western blotting..... 24
3.10 Silver staining... 26
3.11 Commassie blue staining.... 27
3.12 Mass spectrometry and Protein identification .. 27
3.13 Large scale plasmid purification... 28
3.13.1 Grow and concentrate cells .. 28
3.13.2 lyse the cell .... 29
3.13.3 Purification of plasmid DNA by CsCl/Ethidium Bromide
equilibrium centrifugation. . 29
Chapter 4 Results.. 31
4.1. Adenovirus infection introduce 3Xflag VCP overexpression in AGS cell
31
4.2. The Western blotting test 3Xflag VCP immunoprecipitation efficiency 32
4.3. The differences between Mock and VCP IP products ... 32
4.4. Identification and classification of protein IDs ... 33
4.5. The analysis of Metacore software.... 33
4.6. Detecting Akt in the complexes of VCP co-IP . 34
Chapter 5 Discussion. 35
5.1. Analysis protein-protein interactions derived from LC/MS/MS.. 35
5.1.1. Reported Proteins interacting with VCP .. 35
5.1.2. Repetitive appeared Proteins in LC-MS/MS analysis ..... 37
5.1.3. Signal pathway related proteins- .... 39
5.2. A possible role of Akt in AGS cell line .. 43
5.3. Limitation and refinement of co-immunoprecipitaiton . 44
5.4. Future work and perspective.... 45
References: ...... 47
Figures and tables ...... 51
Appendix .... 60
dc.language.isoen
dc.subject訊息傳導zh_TW
dc.subject胃癌zh_TW
dc.subject絡胺酸zh_TW
dc.subject共免疫沉澱zh_TW
dc.subject交互作用體zh_TW
dc.subjectInteractomeen
dc.subjectGastric canceren
dc.subjectSignal transductionen
dc.subjectValosin containing proteinen
dc.subjectco-immunoprecipitationen
dc.title利用蛋白質體技術鑑定於胃癌上皮細胞中缬絡胺酸蛋白質之交互作用體zh_TW
dc.titleProteomics approaches to Identify the Interactome of
Valosin-Containing Protein (VCP) in AGS cell
en
dc.typeThesis
dc.date.schoolyear96-2
dc.description.degree碩士
dc.contributor.oralexamcommittee簡昆鎰,鄭劍廷
dc.subject.keyword胃癌,&#32556,絡胺酸,共免疫沉澱,交互作用體,訊息傳導,zh_TW
dc.subject.keywordGastric cancer,Valosin containing protein,co-immunoprecipitation,Interactome,Signal transduction,en
dc.relation.page69
dc.rights.note有償授權
dc.date.accepted2008-07-30
dc.contributor.author-college醫學院zh_TW
dc.contributor.author-dept生物化學暨分子生物學研究所zh_TW
顯示於系所單位:生物化學暨分子生物學科研究所

文件中的檔案:
檔案 大小格式 
ntu-97-1.pdf
  未授權公開取用
2.08 MBAdobe PDF
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved